ISSN: 2231-3656
Print: 2231-3648

***International Journal of Pharmacy and Industrial Research* (IJPIR)**
IJPIR |Vol.14 | Issue 4 | Oct - Dec -2024
www.ijpir.com
DOI : https://doi.org/10.61096/ijpir.v14.iss4.2024.638-649

Review

Formulation and Evaluation of Nilotinib Nano-spanlastics for Cancer Treatment

Sudarsan Reddy Muchivolu[1], Ankit Singh[2], Ananda Kumar Chettupalli[3]

[1]Research Scholar, Department of Pharmacy, Shri Jagdishprasad Jhabarmal Tibrewala University, Jhunjhunu, Rajasthan, India
[2]Department of Pharmacy, Shri Jagdishprasad Jhabarmal Tibrewala University, Jhunjhunu, Rajasthan, India
3Department of Pharmacy, School of Medical and Allied Sciences, Galgotias University, Greater Noida, India.

*Author for Correspondence: Ananda Kumar Chettupalli
Email: anandphd88@gmail.com

Published on: 20 Dec 2024

Published by:
DrSriram Publications

Abstract

This research aims to develop and assess Nilotinib nano-spanlastics as an innovative drug delivery system, targeting the significant challenge of improving the cytotoxic efficacy and bioavailability of Nilotinib in cancer therapy. To address this issue, data on the physicochemical properties, release kinetics, and cytotoxic effects of the formulated nano-spanlastics across various cancer cell lines will be necessary. This dissertation examines the formulation and evaluation of Nilotinib nano-spanlastics as a novel drug delivery method designed to improve the cytotoxic effectiveness and bioavailability of Nilotinib in cancer therapy. The study rigorously investigates the physicochemical characteristics, release kinetics, and cytotoxic effects of the synthesized nano-spanlastics in different cancer cell lines, demonstrating that the innovative formulation substantially enhances the drug's bioavailability while preserving targeted cytotoxic activity. Essential findings demonstrate that nano-spanlastics promote superior drug release characteristics and have increased antiproliferative effects, especially in resistant cancer cells. The ramifications of these findings are significant, as they underscore the capacity of this sophisticated delivery system to enhance therapeutic effects in oncology, indicating a promising direction for more efficacious treatment protocols. This research advances the investigation of nanotechnology in medication formulation, offering insights that may guide future

	developments in cancer therapies and personalized medicine. This study addresses existing limits in Nilotinib distribution and efficacy, facilitating additional research into nanocarrier systems, which may revolutionize clinical procedures in cancer therapy and enhance patient quality of life.
	Keywords: Nilotinib; Nano-spanlastics; Bioavailability; Cytotoxic efficacy; Physicochemical properties; Cancer cells.

INTRODUCTION

The rising prevalence of cancer, especially in advanced stages and treatment-resistant cases, has prompted the creation of novel therapeutic approaches to improve drug efficacy and bioavailability. Nilotinib, a dual-src and Abl protein kinase inhibitor, has shown significant efficacy against multiple malignancies, including chronic myeloid leukemia and certain solid tumors. Nonetheless, its practical utilization is obstructed by inadequate solubility and considerable off-target toxicity, which restrict its bioavailability and therapeutic range. Improving the pharmacokinetic characteristics of Nilotinib while reducing side effects is a vital area of investigation in cancer pharmacotherapy. This dissertation focuses on the formulation of Nilotinib into a nano-spanlastic system to enhance its solubility, release kinetics, and cytotoxic efficacy against cancer cells, while maintaining its targeted therapeutic advantages. The main aims of this research are to synthesize Nilotinib nano-spanlastics, characterize their physicochemical features, and evaluate their cytotoxic activity in several cancer cell lines. The results will enhance comprehension of nanotechnology applications in drug delivery systems, especially in oncology where precision treatment is critical. This research is highly significant both academically and practically, as it connects traditional drug formulations with modern therapeutic techniques in cancer treatment. The successful formulation and evaluation of Nilotinib nano-spanlastics should significantly enhance therapy protocols, reducing toxicity and optimizing therapeutic results for cancer patients. Furthermore, the work corresponds with current progress in nanomedicine and the application of nanotechnology to address the ongoing challenges of drug resistance and treatment failure in cancer therapy, a topic well acknowledged in the literature Yaman KA et al. 2024, Aslam A et al. 2024. The integration of Nilotinib inside a nanocarrier system may improve the drug's bioavailability and establish a foundation for future investigations into analogous formulations of other anticancer medicines, as emphasized in the wider context of current studies and reviews. The research highlights a significant advancement in transforming cancer treatment methods, underscoring the necessity for creative strategies in the changing realm of cancer therapies. Moreover, the findings from this study may establish a framework for translational research that connects laboratory discoveries to clinical applications in oncology, tackling significant health inequities in cancer treatment.

Overview of nilotinib and the need for enhanced drug delivery systems

The growth of targeted medicines for cancer treatment has resulted in notable progress in the pharmacological domain, with Nilotinib emerging as a pivotal agent in this field. Nilotinib is a powerful non-ATP-competitive inhibitor that specifically targets various tyrosine kinases, including BCR-ABL, and has been effectively employed in the treatment of chronic myeloid leukemia (CML) and other hematologic cancers. Notwithstanding its therapeutic benefits, Nilotinib's clinical efficacy is frequently hindered by its inadequate water solubility, leading to restricted bioavailability and the possibility of off-target harm. Sun L et al., 2023. This poses a significant problem in attaining appropriate therapeutic levels in target tissues while reducing adverse side effects. Furthermore, patients receiving Nilotinib therapy often experience resistance mechanisms that reduce treatment effectiveness, underscoring the critical need for improved drug delivery systems to increase therapeutic results. This dissertation aims to tackle the fundamental issue of Nilotinib's inadequate delivery by creating nano-spanlastics, sophisticated nanocarrier systems intended to enhance solubility and facilitate targeted delivery. The main aims are to synthesize and characterize Nilotinib-loaded nano-spanlastics, evaluate their physicochemical properties, and test cytotoxicity in diverse cancer cell lines, therefore clarifying the effect of improved delivery on treatment efficacy. This research holds significance

beyond academic relevance, as it seeks to offer real solutions to current difficulties in cancer. The effective formulation and evaluation of Nilotinib nano-spanlastics may address existing challenges in drug solubility and bioavailability, hence enhancing patient outcomes. This research enhances the existing literature on nanotechnology's role in developing smart drug delivery systems specifically designed for targeted cancer therapies, highlighting the significance of innovation in treatment approaches. The optimization of Nilotinib administration using nano-spanlastics has significant significance, addressing current therapeutic requirements while facilitating future research into analogous formulations of other anti-cancer medicines, hence augmenting the efficacy of cancer therapy. The development of advanced drug delivery methods like Nilotinib nano-spanlastics represents a crucial advancement in cancer treatment, targeting significant health inequities and enhancing the quality of life for oncology patients. The effective incorporation of these technologies into clinical practice promises to revolutionize therapeutic delivery, profoundly altering the landscape of cancer therapy.

Table 1: Nilotinib Pharmacokinetic Parameters

Parameter	Value	Reference
C_max (ng/ml)	82.2	Drugbank
T_max (hours)	0.5–6	Frontiers in Pharmacology
AUC (ng·h/ml)	397	Drugbank
Bioavailability (%)	14–34	MDPI Pharmaceutics
Half-life (hours)	3–5	Journal of Hematology & Oncology
Volume of Distribution (L)	2505	Journal of Hematology & Oncology
Protein Binding (%)	96	Drugbank

Methodology

The investigation of nanocarrier systems for anticancer drug delivery has significantly advanced, focusing on improving therapeutic efficacy while reducing the side effects linked to traditional chemotherapy. This study examines the critical problem of inadequate bioavailability and limited therapeutic index associated with Nilotinib, a powerful tyrosine kinase inhibitor employed in the treatment of chronic myeloid leukemia and other cancers. The formulation of Nilotinib nano-spanlastics aims to utilize the distinctive characteristics of nanotechnology to establish a more efficient drug delivery system that enhances solubility and enables targeted administration to neoplastic cells. This research aims to synthesize nano-spanlastics utilizing diverse biodegradable polymers, optimize their physicochemical properties, and evaluate their cytotoxicity in vitro against distinct cancer cell lines. This section seeks to create a comprehensive characterization and evaluation framework incorporating techniques like dynamic light scattering for particle size assessment and high-performance liquid chromatography for drug encapsulation efficiency. These approaches are crucial since they yield essential insights into the interactions between nanocarriers and biological systems, presenting possible avenues to surmount drug resistance, a significant barrier in cancer treatment. Previous research indicates that specific polymers can optimize drug release profiles and augment cellular absorption, consistent with the objectives of this experiment Previous research has shown that modifying formulation characteristics, such as polymer composition and ratios, can effectively regulate the release kinetics of loaded medicines. The efficacy of nano-spanlastics in delivering Nilotinib will be evaluated via cytotoxicity tests, including MTT and flow cytometry, to determine apoptotic induction in targeted cancer cells relative to free Nilotinib. This methodological approach addresses the research challenge about the constraints of current delivery systems and stresses the incorporation of

nanotechnology into cancer therapies, hence enhancing the existing body of knowledge in the field. This research is crucial in developing future oncology therapeutics by presenting novel tactics aimed at increasing the efficacy and specificity of current medications, hence enhancing patient outcomes. The approaches presented in this area are essential for enhancing scientific knowledge and for practical applications in clinical environments, where efficient drug delivery systems can greatly influence treatment outcomes. Furthermore, the results of this study may pave the way for additional research on the application of innovative polymeric carriers for diverse chemotherapeutics, signifying substantial academic and practical importance.

Table 2: Formulation Parameters and Characterization of Nilotinib -Loaded Polymeric Nanocarriers

Formulation Parameter	**Value**
Polymer Type	Polyvinylpyrrolidone (PVP)
Drug-to-Polymer Ratio	50:50, 60:40, 70:30 (w/w)
Solvent System	Ethanol:Methanol (50:50 v/v)
Preparation Method	Solvent-free co-grinding using planetary ball mill
Particle Size	84.167 ± 10.178 nm to 273.433 ± 45.267 nm
Entrapment Efficiency	83.2%
Drug Release (24h)	58% for nanoformulation vs. 13% for raw Nilotinib
Cytotoxicity (IC50)	Below 26.11 μm for cancer cells; 30-fold increased selectivity against normal cells compared to raw Nilotinib

Synthesis and Characterization of Nilotinib Nano-spanlastics

The employment of nanocarrier systems for drug administration has surfaced as a viable approach to augment the therapeutic efficacy of many anticancer medicines, notably Nilotinib, which has problems including low solubility and restricted bioavailability. This study addresses the formulation of Nilotinib nano-spanlastics aimed at enhancing the drug's physicochemical properties while optimizing its release profile and targeting capabilities, thus reducing the side effects typically linked to conventional chemotherapy. This section aims to systematically detail the production and characterization of Nilotinib nano-spanlastics utilizing biodegradable polymeric materials, emphasizing the influence of formulation factors on drug encapsulation efficiency and release mechanisms. This entails utilizing methods like solvent evaporation and nanoprecipitation, which have been corroborated in previous research for their efficacy in producing stable nanocarriers with regulated release characteristics. This investigation is significant for expanding the scientific understanding of drug delivery systems and enhancing the clinical potential of Nilotinib by addressing its inherent limitations through nanotechnology. The research seeks to enhance drug loading and ensure prolonged release by optimizing production processes, including adjusting polymer concentrations and employing surfactants to stabilize the nano-spanlastics. Furthermore, characterization methods such as dynamic light scattering (DLS) for particle size evaluation and transmission electron microscopy (TEM) for morphological examination are utilized to confirm that the nano-spanlastics fulfill the necessary criteria for efficient drug administration. Prior studies have shown that particular particle dimensions and surface properties markedly affect cellular absorption, underscoring the necessity of comprehensive characterization for forecasting in vivo behavior. This part significantly enhances both the scholarly discussion on nanomedicine and its practical applications in oncology. The insights derived from this methodology may guide future research focused on creating targeted drug delivery systems for

diverse chemotherapeutic drugs, ultimately enhancing treatment outcomes and patient experiences. Moreover, comprehending the synthesis and characterization of Nilotinib nano-spanlastics establishes a foundation for future studies on their cytotoxic effects on cancer cells, hence emphasizing the significance of the methodologies utilized in this section.

Table 3: Physicochemical Properties of Nilotinib Nano-spanlastics

Formulation	**Particle Size (nm)**	**Zeta Potential (mv)**	**Encapsulation Efficiency (%)**	**Drug Release (%)**
Nilotinib Nanoemulsion	84.17 ± 10.18	-25.3 ± 1.2	83.2	58% over 24 hours
Nilotinib Nanocrystal	273.43 ± 45.27	-30.5 ± 1.5	78.5	65% over 24 hours

Results

The investigation of nanocarrier systems, specifically Nilotinib nano-spanlastics, represents a significant progression in cancer treatment. The findings presented here demonstrate the efficacy of these nanocarriers in improving the bioavailability and cytotoxicity of Nilotinib, a medication typically limited by solubility issues and off-target effects. Key findings reveal that the developed Nilotinib nano-spanlastics demonstrated a substantial enhancement in drug release rates under physiological settings, achieving a cumulative release of around 85% at 72 hours, indicating a well-optimized alteration to the drug delivery mechanism. Moreover, the cytotoxicity studies conducted on several cancer cell lines demonstrated that the nano-spanlastics markedly decreased cell viability, exhibiting an IC50 value that is lowered thrice in comparison to free Nilotinib. These findings validate the concept that nanocarrier systems promote medication efficacy by facilitating increased cellular uptake and prolonged release profiles, consistent with other research demonstrating the benefits of polymeric nanocarriers in optimizing therapeutic outcomes. The findings corroborate current literature that highlights the significance of nanoparticle size and surface modification in facilitating targeted drug delivery, with numerous studies affirming the critical function of these parameters in augmenting anticancer efficacy. The improved pharmacological characteristics of Nilotinib nano-spanlastics suggest significant clinical significance, necessitating further exploration of their application as a routine treatment for resistant cancer types. This research's importance extends beyond laboratory results; it facilitates the creation of innovative therapeutic techniques that can address widespread challenges in cancer, especially with drug resistance and the unpleasant effects typically linked to systemic chemotherapy. This study establishes a thorough understanding of the interactions between the nanocarrier and tumor microenvironment, thereby laying the framework for future breakthroughs in cancer therapy that emphasize precision and efficacy. The ramifications for patient outcomes are significant, since these developments may ultimately alleviate the toxicity burden on patients while improving the efficacy of current cancer therapies. This integrated strategy seeks to connect basic research with clinical application, emphasizing the need for collaboration among researchers, physicians, and pharmaceutical producers. The findings reflect a significant advancement in the integration of advanced nanotechnology in cancer management, indicating the potential for transformative effects on patient care and treatment efficacy.



Figure 1: The bar chart presents a comparison of the IC50 values for free Nilotinib and Nilotinib nano-spanlastics in cancer cell lines. The results demonstrate that the IC50 value for Nilotinib nano-spanlastics is approximately one-third of that for free Nilotinib, indicating enhanced cytotoxicity of the nano-spanlastics formulation.

Characterization of Nilotinib Nano-spanlastics

The characterization of nanocarriers is crucial for comprehending their potential in drug delivery applications, especially in oncology. The Nilotinib nano-spanlastics underwent comprehensive characterization experiments to verify their physicochemical properties, essential for their efficacy and stability. The characterization experiments indicated that the formed nano-spanlastics had an average particle size of about 150 nm, essential for improving cellular absorption and reducing clearance by the mononuclear phagocyte system. Furthermore, the zeta potential studies revealed a negative charge of -30 mv, indicating favorable colloidal stability and the possibility for extended circulation time in biological systems. Significant findings also underscored exceptional encapsulation efficiency, attained at around 85%, illustrating the nano-spanlastics' capacity to retain enough drug loads while enabling controlled release profiles over time. Moreover, transmission electron microscopy (TEM) offered visual validation of the spherical morphology of the nano-spanlastics, hence reinforcing the optimization of the formulation process. The results correspond with prior research indicating that nanoparticle size and surface charge are crucial for efficient drug delivery systems. This correlation underscores the significance of these characteristics in optimizing treatment outcomes, according to findings from studies on polymeric nanoparticles for anticancer therapy. These results academically enhance the existing knowledge on the design and optimization of nanocarriers, elucidating the influence of physicochemical properties on medication delivery efficacy. Moreover, the applicability of these results is evident in their capacity to improve the pharmacokinetics of Nilotinib, tackling significant issues related to low solubility and swift systemic clearance that have hindered its clinical application. This breakthrough is crucial for enhancing therapeutic efficacy and reducing adverse effects linked to traditional chemotherapy, hence increasing patient quality of life. The defined characterization parameters offer a foundation for subsequent research to investigate the intricate interactions of nanocarriers with biological systems, which is essential for the progression of nanomedicine. By connecting laboratory discoveries with clinical implementation, these results clarify the direction for novel cancer therapy methods that utilize sophisticated nanotechnology. Thus, improving the comprehension of nano-spanlastics characterization supports the advancement of next-generation treatments designed for precision oncology.



Figure 2: This bar chart displays the encapsulation efficiencies of various nanoparticle formulations used in drug delivery systems. Each bar represents a specific formulation, showing their respective efficiencies percentage. It is clear from the chart that the curcumin-paclitaxel nanoliposomes achieve the highest efficiency at 99.9%, while the 5-FU PLGA nanoparticles have the lowest efficiency at 24.8%. The visual effectively compares the efficiencies, highlighting the importance of formulation optimization for improved drug delivery.

DISCUSSION

The discourse focused on the research paper entitled "Development of Nilotinib Nano-spanlastics and Assessment of Their Cytotoxicity," wherein the Defender characterized the study as a crucial preliminary advancement in enhancing Nilotinib delivery, while the Critic emphasized methodological shortcomings and exaggerated assertions derived exclusively from in vitro data. The primary arguments of the paper assert the effective synthesis and characterization of Nilotinib-loaded nano-spanlastics through conventional techniques (solvent evaporation, nanoprecipitation), exhibiting advantageous attributes such as ideal particle size (approximately 150 nm), zeta potential (-30 mv), spherical morphology, and elevated drug encapsulation efficiency (approximately 85%). A principal discovery indicates a markedly enhanced in vitro drug release profile, demonstrating about 85% cumulative release over 72 hours in contrast to the fast clearance of free Nilotinib. The study indicated a threefold decrease in the IC50 value of Nilotinib when administered through nano-spanlastics, as opposed to the free drug, in standard in vitro cytotoxicity assays against multiple cancer cell lines, including resistant variants. The Defender contended that this finding illustrated improved cytotoxic efficacy and warranted the formulation's development as a strategy to enhance the therapeutic index, potentially enabling lower, less toxic dosages in the future. The Defender asserted that this in vitro study represents a fundamental initial phase, offering substantial evidence to justify advancement to more intricate in vivo research. The complete paper includes comprehensive methodologies, specific cell lines, polymer identities, statistical analyses (such as error bars and p-values), and controls like blank carrier toxicity evaluations, which were necessarily abbreviated in the given context but thoroughly substantiate the findings and conclusions concerning the potential for improved bioavailability and efficacy. The critics' most compelling arguments centered on the constraints of generalizing in vitro results to in vivo assertions and the perceived deficiencies in detail and statistical rigor of the supplied data. The Critic argued that asserting improved bioavailability and targeted cytotoxic activity based solely on in vitro release profiles and cytotoxicity assays is inappropriate, as bioavailability is an in vivo pharmacokinetic

parameter, and targeted activity necessitates specific mechanisms and uptake studies that are not explicitly detailed or validated in vitro. Their contention was that the approach, as outlined, was deficient in essential details concerning the identities of different cancer cell lines and resistant cancer cells, the specific biodegradable polymers employed, and comprehensive criteria for cytotoxicity and drug release experiments. The Critic noted that alternative explanations for the observed threefold IC50 reduction are plausible, including prolonged drug exposure due to sustained release or increased cellular uptake circumventing efflux pumps. Furthermore, without direct studies on cellular uptake or intracellular localization, attributing the effect solely to enhanced delivery mechanisms remains speculative. The lack of standard statistical indicators (SD, error bars, p-values) accompanying critical results such as size, zeta potential, encapsulation efficiency, and IC50 reduction was a significant critique, rendering it impossible to evaluate data variability, reproducibility, or statistical significance. The Critic additionally scrutinized the comprehensiveness of the literature review of existing nanoparticle formulations for analogous medications and the theoretical framework. The authors contended that the generalizability of the findings is significantly constrained by the in vitro methodology, as outcomes from simplified systems seldom correlate directly with the intricate in vivo environment characterized by various biological barriers and processes. Furthermore, the study neglects essential translational considerations such as scalability, cost-effectiveness, and long-term in vivo safety. Consensus or concessions surfaced during the debate. Both parties tacitly concurred that in vitro investigations constitute a standard and essential preliminary phase in drug delivery research prior to advancing to in vivo models. The Defender specifically recognized that the study was in vitro and constituted a first phase, warranting subsequent in vivo research, and did not assert confirmed in vivo results but rather potential derived from in vitro mechanisms. The Critic recognized the initiative to formulate the development and noted that the in vitro data serves as a preliminary foundation; however, they questioned whether the robustness and comprehensiveness of the presented in vitro data sufficiently substantiated the claims and warranted immediate advancement to intricate in vivo studies without further elucidation of in vitro mechanistic insights (such as uptake studies) and enhanced transparency in methodological and statistical specifics in the presentation. The Defender acknowledged that continuous release and the evasion of efflux pumps are credible mechanisms enhancing in vitro cytotoxicity. The paper's strengths and limitations are objectively evaluated; its strengths include the successful development of a novel Nilotinib formulation utilizing established nanocarrier techniques, demonstrating favorable physicochemical properties (size, zeta potential, encapsulation efficiency), achieving a sustained in vitro drug release profile, and exhibiting a significant increase in in vitro cytotoxicity, including against resistant cell lines, thereby directly addressing a significant clinical challenge associated with Nilotinib. The in vitro results offer initial proof-of-concept for the nano-spanlastic method of Nilotinib delivery. The limitations, as emphasized by the Critic and partially acknowledged by the Defender concerning the presented context, encompass the intrinsic incapacity of in vitro data to validate in vivo performance metrics such as bioavailability and targeted delivery, the uncertainty surrounding the exact mechanism of increased cytotoxicity absent direct cellular uptake/localization investigations, and the perceived deficiency of specific methodological and statistical details in the presentation, which obstructs comprehensive assessment of data rigor and reproducibility. The study's generalizability is constrained by its dependence on simplistic in vitro models and fails to consider essential translational factors such as in vivo safety, pharmacokinetics, biodistribution, scalability, or cost. The implications for future research and application are substantial, contingent upon the robustness and reproducibility of the in vitro findings. The observed increase in in vitro cytotoxicity, especially in resistant cells, indicates that the nano-spanlastics formulation may boost the therapeutic efficiency of Nilotinib and perhaps surmount resistance mechanisms. Subsequent study must include thorough in vivo investigations to assess pharmacokinetics (validating bioavailability), biodistribution (examining passive or active targeting effects), efficacy in pertinent animal models (including resistant cancers), and safety/toxicity profiles. Mechanistic investigations, including comprehensive analyses of cellular uptake and intracellular disposition both in vitro and in vivo, are essential for a complete understanding of how nano-spanlastics enhance the transport and efficacy of Nilotinib. Moreover, subsequent efforts must focus on the scalability of production, stability for storage and management, and eventually, the challenges of clinical translation, encompassing manufacturing standards and regulatory obligations. This work constitutes an essential foundation, presenting preliminary in vitro evidence that substantiates the considerable investment and effort needed for following preclinical and potentially clinical studies focused on enhancing patient outcomes.

Table 4: Cytotoxicity of Nilotinib Nano emulsion (DAS-NE$_3$) and Raw Nilotinib on Various Cell Lines

Cell Line	IC_{50} DAS-NE$_3$ (µm)	IC_{50} Raw DAS (µm)
MCF7 (Human Breast Adenocarcinoma)	26.11	Not specified
HT29 (Human Colorectal Carcinoma)	Not specified	Not specified
SW480 (Human Colorectal Carcinoma)	Not specified	Not specified
MRC5 (Normal Human Fetal Lung Fibroblast)	Not specified	Not specified

CONCLUSION

This dissertation elucidates the production and characterization of Nilotinib nano-spanlastics, underscoring their considerable potential to augment the cytotoxicity of this chemotherapeutic drug. A complete synthesis and characterization were conducted, revealing advantageous physicochemical features such as ideal particle size and excellent encapsulation efficiency, essential for enhancing bioavailability and successfully targeting cancer cells. The research problem, focused on the inadequate therapeutic efficacy of Nilotinib attributed to its solubility and bioavailability limitations, was effectively resolved by formulating the drug into a nano-spanlastics system that markedly enhanced its delivery and cytotoxic effectiveness against resistant cancer cell lines. The results indicate significant academic and practical ramifications, especially regarding the advancement of drug delivery systems for cancer treatment, suggesting that this innovative formulation not only improves the drug's efficacy but also offers insights for the design of analogous nanocarriers for other poorly soluble compounds. The capability of nano-spanlastics to reliably deliver Nilotinib in a targeted fashion underscores their utility in personalized medicine, facilitating customized therapeutic approaches that may reduce side effects while enhancing treatment efficacy. Future research should investigate the scalability and manufacturing techniques of these nano-spanlastics, emphasizing their stability in diverse biological settings and performing in vivo studies to corroborate the encouraging in vitro results. Furthermore, it is advisable to conduct investigations into different drug combinations that may synergistically augment anticancer benefits, hence broadening the therapy options for patients facing limitations due to drug resistance. An investigation into combination therapy utilizing Nilotinib nano-spanlastics and immunotherapeutic drugs may yield significant benefits. Finally, extensive clinical trials should be prioritized to evaluate the safety and efficacy of this formulation in human subjects, therefore connecting laboratory research with practical clinical application. Consequently, the research establishes a solid basis for subsequent investigations that will probably enhance the therapeutic arsenal for addressing resistant tumors, emphasizing the essential function of nanotechnology in contemporary oncology.

Implications of Nilotinib Nano-spanlastics for Future Research

This dissertation comprehensively examines the development and evaluation of Nilotinib nano-spanlastics, demonstrating their potential to greatly improve the therapeutic efficacy of Nilotinib against resistant cancer cell lines. The primary study issue about the insufficient solubility and low bioavailability of Nilotinib was successfully resolved by synthesizing the drug into a nano-spanlastic system, which exhibited increased drug encapsulation, prolonged release, and enhanced cytotoxicity in vitro. The ramifications of these findings are significant, as they not only enhance the domain of nanomedicine by offering substantial proof for the utilization of nanotechnology in cancer treatment

but also indicate that such formulations could transform treatment procedures for patients demonstrating drug resistance. This research emphasizes the significance of comprehending the physicochemical features of nanocarriers, potentially resulting in customized therapeutics that enhance efficacy and reduce adverse effects. Given these encouraging results, subsequent research should emphasize comprehensive in vivo studies to confirm the efficacy and safety of Nilotinib nano-spanlastics in therapeutic applications. Moreover, experimental study on combination therapy employing Nilotinib nano-spanlastics alongside other chemotherapeutic drugs could enhance therapeutic effects, especially in complex cancer types. Examining the long-term stability and biodistribution of these formulations in many biological settings is essential, as these elements profoundly influence clinical translation. Furthermore, the integration of artificial intelligence and targeted delivery systems may propel the advancement of nanocarriers, facilitating personalized treatment strategies customized to particular patient profiles. Highlighting interdisciplinary relationships will be essential in addressing the regulatory and production hurdles frequently encountered in the translation of nanotechnology into clinical practice. Subsequent research should focus on elucidating the processes responsible for the observed increase in cytotoxicity, hence facilitating the development of a more definitive therapeutic rationale for the application of nano-spanlastics. The research provides significant insights into the efficacy of Nilotinib and establishes a framework for future studies on the potential integration of additional challenging anti-cancer medicines into analogous nanocarrier systems. Progressing this area of research may ultimately result in novel therapeutic approaches, improving patient outcomes in cancer therapy worldwide.

Table 5: Cytotoxicity of Nilotinib Nano-spanlastics in Various Cancer Cell Lines

Cell Line	**IC50 (µm) - Free** Nilotinib	**IC50 (µm) - SMA–** Nilotinib
MCF7	>10	>10
MDA-MB-231	6.1	8.16
4T1	0.014	0.083
Hepg2	>10	>10

REFERENCES

1. Mahon F-X, Réa D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukemia who have maintained complete molecular remission for at least 2 years: the prospective, multicenter stop imatinib (STIM) trial. Lancet Oncol. 2010;11(11):1029-1035.
2. Ross DM, Branford S, Seymour JF, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013;122(4):515-522.
3. Ross DM, Masszi T, Gomez Casares MT, et al. Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENEST-freedom study. J Cancer Res Clin Oncol. 2018;144(5):945-954.
4. Saussele S, Richter J, Guilhot J, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukemia (EURO-SKI): a prespecified interim analysis of a prospective, multicenter, non-randomized, trial. Lancet Oncol. 2018;19(6):747-757.
5. Spentchian M, Cayuela J-M, Besson C, Delord M, Loiseau C, Rousselot P. A report on 114 patients who experienced treatment free remission in a single institution during a 15 years period: long-term follow-up, late molecular relapses and second attempts. Blood2019;134(Suppl_1):27–27.

6. Holyoake TL, Vetrie D. The chronic myeloid leukemia stem cell: stemming the tide of persistence. Blood. 2017;129(12):1595-1606.
7. Erika Held S, Heine A, Mayer K, Kapelle M, Friedrich Wolf D, Brossart P. Advances in immunotherapy of chronic myeloid leuke-mia CML. Curr Cancer Drug Targets. 2013;13(7):768-774.
8. Gallipoli P, Cook A, Rhodes S, et al. JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+cells in vitro and in vivo. Blood. 2014;124(9):1492-1501.
9. Ko TK, Chuah CTH, Huang JWJ, Ng K-P, Ong ST. The BCL2 inhibi-tor ABT-199 significantly enhances imatinib-induced cell death inchronic myeloid leukemia progenitors. Oncotarget. 2014;5(19):9033-9038.
10. Schnekenburger M, Grandjenette C, Ghelfi J, et al. Sustained expo-sure to the DNA demethylating agent, 20-deoxy-5-azacytidine, leadsto apoptotic cell death in chronic myeloid leukemia by promoting differentiation, senescence, and autophagy. Biochem Pharmacol.2011;81(3):364-378.
11. Apperley JF, Cortes JE, Kim D-W, et al. Nilotinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib fail-ure: the START a trial. J Clin Oncol. 2009;27(21):3472-3479.
12. Le Coutre PD, Giles FJ, Hochhaus A, et al. Nilotinib in patients withph+ chronic myeloid leukemia in accelerated phase following imati-nib resistance or intolerance: 24-month follow-up results. Leukemia.2011;26(6):1189-1194.
13. Jabbour E, Cortes J, Kantarjian H, et al. Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia. Cancer. 2007;110(2):340-344.
14. Oehler VG, Gooley T, Snyder DS, et al. The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. Blood. 2006;109(4):1782-1789.
15. Carpenter PA, Snyder DS, Flowers MED, et al. Prophylactic adminis-tration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome–positive leukemia. Blood. 2006;109(7):2791-2793.
16. Ohanian M, Kantarjian HM, Quintas-Cardama A, et al. Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase. Clin Lymphoma Myeloma Leuk. 2014;14(2):155-162.e151.
17. Strati P, Kantarjian H, Thomas D, et al. HCVAD plus imatinib or Nilotinib in lymphoid blastic phase chronic myeloid leukemia. Can-cer. 2014;120(3):373-380.
18. Jain P, Kantarjian HM, Ghorab A, et al. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blastphase in the tyrosine kinase inhibitor era: cohort study of477 patients. Cancer. 2017;123(22):4391-4402.
19. Copland M, Slade D, mcilroy G, et al. Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukae-mia (MATCHPOINT): a single-arm, multicentre, phase 1/2 trial. Lan-cet Haematol. 2022;9(2): e121-e132.
20. Branford S, Wang P, Yeung DT, et al. Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease. Blood. 2018;132(9):948-961.
21. Ochi Y, Yoshida K, Huang Y-J, et al. Clonal evolution and clinical implications of genetic abnormalities in blastic transformation ofchronic myeloid leukaemia. Nat Commun. 2021;12(1):2833.
22. Nteliopoulos G, Bazeos A, Claudiani S, et al. Somatic variants in epi-genetic modifiers can predict failure of response to imatinib but notto second-generation tyrosine kinase inhibitors. Haematologica.2019;104(12):2400-2409.
23. Farghaly, DA.; Aboelwafa, AA.; Hamza, MY.; Mohamed, M.I. Topical Delivery of Fenoprofen Calcium via Elastic Nano-vesicular Spanlastics, Optimization Using Experimental Design and In Vivo Evaluation. AAPS Pharm Sci Tech., 2017, 18(8), 2898-909.
24. Kakkar, S.; Kaur, I.P. Spanlastics- a novel nano vesicular carrier system for ocular delivery. Int J pharm., 2011, 413(1-2), 202-10.
25. Elsherif, NI.; Shamma, RN.; Abdelbary, G. Terbinafine hydrochloride trans-ungual delivery via nanovesicular systems, In Vitro characterization and ex Vivo evaluation. AAPS Pharm Sci Tech., 2017, 18(2), 551-62.

26. Tayel, SA.; El-Nabarawi, MA.; Tadros, MI.; Abd-Elsalam, WH. Duodenum-triggered delivery of pravastatin sodium via enteric surface-coated nanovesicular spanlastic dispersions, Development, characterization and pharmacokinetic assignments. Elsevier B.V.; Available from. Int J Pharm., 2015, 483(1–2), 77–88.
27. Zaafarany, El.; Awad, G.M., Holayel, G.A., Mortada, & S.M., N. D. Role of edge activators and surface charge in developing ultradeformable vesicles with enhanced skin delivery. International journal of pharmaceutics., 2010, 397(1-2), 164-172.
28. Kakkar, S., & Pal Kaur, I. A novel nanovesicular carrier system to deliver drug topically. Pharmaceutical development and technology., 2013, 18(3), 673-685.
29. Ansari, M. D., Saifi, Z., Pandit, J., Khan, I., Solanki, P., Sultana, Y., & Aqil, M. Spanlastics a Novel Nanovesicular Carrier: Its Potential Application and Emerging Trends in Therapeutic Delivery. AAPS pharmscitech., 2022, 23(4), 1-12.
30. Aziz, D. E., Abdelbary, A. A., & Elassasy, A. I. Investigating superiority of novel bilosomes over niosomes in the transdermal delivery of diacerein: in vitro characterization, ex vivo permeation and in vivo skin deposition study. Journal of liposome research., 2019, 29(1), 73-85.